Economic Growth - US GDP grew by 43% in Q3 [1] - The actual growth of 43% surpassed expectations of 32% [1]

Legal & Investigative - Epstein investigation releases new documents [1] - Documents contain Trump's name in multiple places [1] - References include flight records related to Epstein's private jet [1]

New trove of documents in Epstein investigation is released with Trump's name in many places, including references to flight records related to Epstein's private jet. Follow live updates: https://t.co/sMKQ3Dpnoh https://t.co/aqShJ6hVtE ...

🚀 Unlock the Full BitMart VIP Experience!✨ Maximize Earnings: Up to 50K USDT Savings Bonus💎 Spend & Earn: BitMart Card + Cashback🔍 Smart Tools: Partner Platforms & AI Insights👑 Elite Access: Exclusive Community & Airdrop Priority👉 Upgrade: https://t.co/UevYPgXqLq https://t.co/rkwpvdyw8E ...

we will make it.Michael Saylor (@saylor):Ride the ₿ear. https://t.co/IzYPRiLd7y ...

https://t.co/9yfILyLw3z ...

📣 Meet the platform that has single-handedly driven activity in the @BNBChain ecosystem in 2025...@fourdotmemezh is the go-to launch platform for $BNB ecosystem participants and its monthly revenue has exceeded $5 million despite a wider market pullback.We've made the ultimate guide to this popular platform so you can understand what it is, how it works, and how to get started ⬇️https://t.co/kFAcTJWSFC ...

RT CoinDesk Podcast Network (@CoinDeskPodcast)🎧 Catch the latest episode of 'THE MINING POD,’ in partnership with @blockspace!THE MINING POD:The Year of the Bitcoin ETF w/ Jean-Marie MognettiJean-Marie Mognetti, CEO of CoinShares, joinsThe Mining Pod to talk about the financialization of Bitcoin following the ETF launches.Notes:* EU ETF market 10x smaller than US* Bitcoin futures in backwardation* Spot liquidity is currently thin* Options market suppressing volatility* US dominates global crypto trading* So ...

Market Dynamics & Competitive Advantage - Novo Nordisk's CEO announces the upcoming launch of the Wegovy pill, an oral GLP-1 medication, with an expected launch in January, providing a first-mover advantage against Eli Lilly, whose pill is expected in March [1][2] - The Wegovy pill boasts a 17% efficacy rate with regular use, leading to 20% weight loss in one in three patients [3] - Novo Nordisk emphasizes the Wegovy pill's efficacy is comparable to injectable GLP-1s, offering patients a choice between injection and pill form with similar results [5] - Novo Nordisk highlights its over 10 years of safety data and cardiovascular protection benefits associated with the Wegovy pill [5][6] Sales & Distribution Strategy - The Wegovy pill will be available through Novo Nordisk's website (Novo Care Pharmacy), partners like LifeMD, Costco, Weight Watchers, and traditional pharmacy channels [7][8] - Novo Nordisk expresses confidence in meeting the demand for the Wegovy pill at launch, despite past supply challenges [9] Innovation & Production - Novo Nordisk overcame scientific skepticism to develop a peptide-based pill with high efficacy, produced at scale [9][10][12] Market Expansion & Pricing - The availability of the Wegovy pill is expected to expand the GLP-1 market by attracting individuals who are averse to injections [13][14] - Novo Nordisk aims to offer the Wegovy pill at an affordable price, starting at $149, to broaden access [12][15] Strategic Outlook & M&A - Novo Nordisk aims to sustain its leadership in diabetes and obesity treatments and is open to M&A opportunities to enhance its pipeline [17][18] - The company aims to capture as many patients as possible from the large pool of approximately 2 billion people suffering from diabetes and overweight [17]

A family trust linked to South African tycoon Koos Bekker sold 2.5 billion rand ($150 million) of Naspers shares to finance the construction of hotels in South Africa, the UK and Italy https://t.co/qzJJRjFaUj ...